Novartis AG (NVS) operating KPIs

• Novartis AG's fiscal year ends on 31/12 (Q1: 31/03, Q2: 30/06, Q3: 30/09, Q4: 31/12); consolidated IFRS financial statements are prepared in millions of USD ($m).
• Following the completion of the spin-off of the generic/biosimilar business Sandoz on 04/10/2023, Novartis operates as a pure-play Innovative Medicines company. All FTE headcount, manufacturing sites, patient reach, and environmental figures in the table reflect continuing operations (ex-Sandoz) without mixing historical data.
• Standalone financial statements of parent company Novartis AG are prepared under the Swiss Code of Obligations in CHF on an annual basis (unlike quarterly IFRS/USD and as a holding company), so Consolidated − Standalone subtraction does not apply.
• Group 11 at the bottom of the table retains all current records and fills in missing Net sales figures as well as Q1, Q3, Q4, and the latest period Q3 2026 from Form 6-K.

Not shown because recent periods are missing (92)

• Total electricity consumption covered by contractual instruments — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Electricity covered by bundled contractual instruments — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Electricity covered by unbundled contractual instruments — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• GHG emissions covered by carbon removal credits — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• GHG emissions covered by biomethane certificates — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• GHG emissions covered by sustainable aviation fuel (SAF) certificates — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Employees covered by regular pay equity study for total pay — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Employees covered by analysis of potential bias for key human resource processes — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Annual average training hours per employee — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Number of countries with community health initiatives launched — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Anti-bribery - Employees trained — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Manufacturing sites with a certified quality management system (ISO 9001 or ISO 13485 certification) — Only annual figures for FY2025 published for the first time (FY2024 column indicates n/a or n/r in ESG Data Summary 2025), lacking 2 consecutive years FY2024–FY2025.
• Projects entering confirmatory development pipeline — Discontinued disclosure in Report on Nonfinancial Matters from FY2024–FY2025 (only FY2020–FY2023 available).
• US FDA Breakthrough Therapy Designations received — Discontinued separate disclosure of the number of FDA Breakthrough Therapy Designations from FY2024–FY2025 (only FY2020–FY2023 available).
• Annual average learning hours per employee (all learning) — Changed definition in FY2025 to mandatory training hours (4 hours, no comparative figures disclosed for 2024), breaking the 2022–2024 total learning hours series at FY2025.
• Scemblix — Japan 1L CML NBRx share (IQVIA quarterly, lagged 1Q) — IQVIA Japan chart lags by 1 quarter (the Q3 2026 slide only has data through Q2 2026 = 56%, missing the latest FY2026Q3 period).
• Rhapsido — US CSU NBRx market share — Q2 2026 slide does not directly print Rhapsido's NBRx market share figure (only Q1 2026 = 24% and Q3 2026 = 26%, missing quarter FY2026Q2).
• Conflict Minerals — In-scope suppliers surveyed — Novartis discontinued filing Form SD (Conflict Minerals) reports starting fiscal year FY2024 following the Sandoz spinoff (series ends at FY2023).
• Conflict Minerals — Supplier CMRT responses received — Novartis discontinued filing Form SD (Conflict Minerals) reports starting fiscal year FY2024 following the Sandoz spinoff (series ends at FY2023).
• Conflict Minerals — Unique smelters/refiners identified — Novartis discontinued filing Form SD (Conflict Minerals) reports starting fiscal year FY2024 following the Sandoz spinoff (series ends at FY2023).
• Conflict Minerals — RMAP Conformant smelters/refiners — Novartis discontinued filing Form SD (Conflict Minerals) reports starting fiscal year FY2024 following the Sandoz spinoff (series ends at FY2023).
• Conflict Minerals — RMAP Active smelters/refiners — Novartis discontinued filing Form SD (Conflict Minerals) reports starting fiscal year FY2024 following the Sandoz spinoff (series ends at FY2023).
• Target Patient Populations (Epidemiology) — Heart failure prevalence (US/EU5/CN/JP) — Target Patient Populations document was not published in 2024 (only 2023, 2025, 2026 — missing FY2024, breaking 2 consecutive years) and represents unverified third-party epidemiological estimates.
• Major facility — Ljubljana, Slovenia (Small Molecules Hub) — Ljubljana facility was first included in the Major facilities table of Form 20-F in FY2025 (144.717 m²), lacking FY2024 figures to form 2 consecutive years.
• Adakveo Revenue (Oncology) — Divested (ophthalmology to Bausch+Lomb / anti-infectives / Sandoz) or downscaled and removed from separate disclosure in Form 6-K (last period: FY2023Q4, missing FY2026Q1–Q3).
• Afinitor/Votubia Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / anti-infectives / Sandoz) or downscaled and removed from separate disclosure in Form 6-K (last period: FY2023Q4, missing FY2026Q1–Q3).
• Beovu Revenue (Other Promoted Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2023Q3, missing FY2026Q1–Q3)
• Exjade/Jadenu Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2022Q4, missing FY2026Q1–Q3)
• Galvus Group Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2025Q4, missing FY2026Q1–Q3)
• Gilenya Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2024Q4, missing FY2026Q1–Q3)
• Gleevec/Glivec Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / anti-infectives / Sandoz) or downscaled and removed from separate disclosure in Form 6-K (last period: FY2023Q4, missing FY2026Q1–Q3).
• Mayzent Revenue (Neuroscience) — Divested (ophthalmology to Bausch+Lomb / anti-infectives / Sandoz) or downscaled and removed from separate disclosure in Form 6-K (last period: FY2023Q4, missing FY2026Q1–Q3).
• Neoral/Sandimmun(e) Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2022Q4, missing FY2026Q1–Q3)
• Onbrez Breezhaler Revenue (Respiratory) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2019Q4, missing FY2026Q1–Q3)
• Other Respiratory Revenue (Other Promoted Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2023Q3, missing FY2026Q1–Q3)
• Seebri Breezhaler Revenue (Respiratory) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2019Q4, missing FY2026Q1–Q3)
• Subtotal COPD 1 Portfolio Revenue (Respiratory) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2019Q3, missing FY2026Q1–Q3)
• Subtotal COPD 2 Portfolio Revenue (Respiratory) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2018Q4, missing FY2026Q1–Q3)
• Tabrecta Revenue (Oncology) — Divested (ophthalmology to Bausch+Lomb / anti-infectives / Sandoz) or downscaled and removed from separate disclosure in Form 6-K (last period: FY2023Q4, missing FY2026Q1–Q3).
• Topical Olopatadine Group Revenue (Ophthalmology) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2018Q4, missing FY2026Q1–Q3)
• Travoprost Group Revenue (Ophthalmology) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2019Q4, missing FY2026Q1–Q3)
• Ultibro Breezhaler Revenue (Respiratory) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2019Q4, missing FY2026Q1–Q3)
• Ultibro Group Revenue (Other Promoted Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2023Q3, missing FY2026Q1–Q3)
• Voltaren/Cataflam Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2022Q4, missing FY2026Q1–Q3)
• Votrient Revenue (Oncology) — Divested (ophthalmology to Bausch+Lomb / anti-infectives / Sandoz) or downscaled and removed from separate disclosure in Form 6-K (last period: FY2023Q4, missing FY2026Q1–Q3).
• Xiidra Revenue (Other Promoted Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2023Q3, missing FY2026Q1–Q3)
• Zortress/Certican Revenue (Established Brands) — Divested (ophthalmology to Bausch+Lomb / antibiotics / Sandoz) or scaled down and removed from separate Form 6-K disclosure (last period: FY2022Q4, missing FY2026Q1–Q3)
• U.S. / Rest of World Revenue Breakdown for Myfortic (Top 20 Table) — Rotates in and out of the #20 position on the Top 20 table each quarter, so the U.S./RoW breakdown is missing for FY2026Q1–Q3 (total global revenue remains fully reported on the table)
• U.S. / Rest of World Revenue Breakdown for Lucentis (Top 20 Table) — Rotates in and out of the #20 position on the Top 20 table each quarter, so the U.S./RoW breakdown is missing for FY2026Q1–Q3 (total global revenue remains fully reported on the table)
• U.S. / Rest of World Revenue Breakdown for Piqray/Vijoice (Top 20 Table) — Rotates in and out of the #20 position on the Top 20 table each quarter, so the U.S./RoW breakdown is missing for FY2026Q1–Q3 (total global revenue remains fully reported on the table)
• Gross-to-Net Deductions by Sub-Channel (NonUSspecificHealthcarePlansAndProgramRebatesMember) — Novartis discontinued separate disclosure of the 3 discount sub-channels starting from the FY2022 Form 20-F (series ends at FY2021)
• Gross-to-Net Deductions by Sub-Channel (NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember) — Novartis discontinued separate disclosure of the 3 discount sub-channels starting from the FY2022 Form 20-F (series ends at FY2021)
• Gross-to-Net Deductions by Sub-Channel (USspecificHealthcarePlansAndProgramRebatesMember) — Novartis discontinued separate disclosure of the 3 discount sub-channels starting from the FY2022 Form 20-F (series ends at FY2021)
• Novartis Finance S.A. (Luxembourg) — EUR 1250M Bond (0.000%, 2017–2021) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2020), lacking 2 consecutive years across FY2024–FY2025
• Novartis Finance S.A. (Luxembourg) — EUR 1250M Bond (0.125%, 2016–2023) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2022), lacking 2 consecutive years across FY2024–FY2025
• Novartis AG (Switzerland) — CHF 500M Bond (0.25%, 2015–2025) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2024), lacking 2 consecutive years across FY2024–FY2025
• Novartis Finance S.A. (Luxembourg) — EUR 750M Bond (0.500%, 2018–2023) — Bond matured and settled before FY2025 or newly issued in its first year (FY2018..FY2022), lacking 2 consecutive years across FY2024–FY2025
• Novartis Finance S.A. (Luxembourg) — EUR 600M Bond (0.75%, 2014–2021) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2020), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1000M Bond (1.750%, 2020–2025) — Bond matured and settled before FY2025 or newly issued in its first year (FY2020..FY2024), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1000M Bond (1.800%, 2017–2020) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2019), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1000M Bond (2.400%, 2017–2022) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2021), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1500M Bond (2.4%, 2012–2022) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2021), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1750M Bond (3.0%, 2015–2025) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2024), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 2150M Bond (3.4%, 2012–2042) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2023), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 700M Bond (3.900%, 2025–2028) — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1750M Bond (4.100%, 2025–2030) — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 925M Bond (4.300%, 2025–2032) — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 1000M Bond (4.4%, 2010–2020) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2019), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 925M Bond (4.600%, 2025–2035) — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• Other — USD 3000M Bond (5.125%, 2009–2019) — Bond matured and settled before FY2025 or newly issued in its first year (FY2017..FY2018), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 350M Bond (5.200%, 2025–2045) — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — USD 550M Bond (5.300%, 2025–2055) — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• Novartis Capital Corporation (US) — SOFR0.52USD800Million20252028NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt100.000 — Bond matured and settled before FY2025 or newly issued in its first year (FY2025..FY2025), lacking 2 consecutive years across FY2024–FY2025
• FTE Headcount Matrix for FY2016–FY2022 (101.703–125.161 FTE) — Includes both Sandoz (spun off 10/2023) and Alcon (spun off 4/2019), not restated by the company under the Region × Function matrix prior to FY2023; excluded to avoid mixing two scopes on the same line.
• Historical Segment — InnovativeMedicines — Following the completion of the Sandoz spin-off on 04/10/2023, Novartis operates as an innovative medicines company with a single operating segment; legacy segment data ends as of FY2022 / Q2 2023
• Historical Segment — Sandoz — Following the completion of the Sandoz spin-off on 04/10/2023, Novartis operates as an innovative medicines company with a single operating segment; legacy segment data ends as of FY2022 / Q2 2023
• Historical Segment — Alcon — Following the completion of the Sandoz spin-off on 04/10/2023, Novartis operates as an innovative medicines company with a single operating segment; legacy segment data ends as of FY2022 / Q2 2023
• Historical Segments — Corporate — Following the completion of the Sandoz spin-off on 04/10/2023, Novartis operates as an innovative medicines company with a single operating segment; legacy segment data ends as of FY2022 / Q2 2023
• Novartis Grimsby Limited (00170180) — Percentage of Female Employees Receiving Bonus (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Lower-Middle Quartile (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Lower Quartile (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Top Quartile (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Upper-Middle Quartile (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Percentage of Male Employees Receiving Bonus (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Mean Gender Bonus Gap (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Mean Gender Hourly Pay Gap (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Median Gender Bonus Gap (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• Novartis Grimsby Limited (00170180) — Median Gender Hourly Pay Gap (%) — The Grimsby plant in the UK transferred ownership in 2021; UK Gender Pay Gap reporting ended at FY2020.
• FRED MRTSSM44611USS — US Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($m, Census) — U.S. Census Bureau pharmacy retail survey data has only been published through 2026-08 (a 1-month lag compared to the company's latest period of 2026-09 and the BLS/Fed H.10 series).
• FRED MRTSSM44611USN — US Retail Sales — Pharmacies and Drug Stores, Not Seasonally Adjusted ($m, Census) — U.S. Census Bureau pharmacy retail survey data has only been published through 2026-08 (a 1-month lag compared to the company's latest period of 2026-09 and the BLS/Fed H.10 series).
• Daily Share Repurchase Transaction Log on SIX — The company only discloses sporadic individual trading days on the SIX 2nd line (62 scattered sessions from 7–10/2026) and does not publish monthly summary tables; daily data is not aggregated into months (official quarterly figures from the cash flow statement were used).
• SASB HC-BP-240b.2 & HC-BP-240b.3 — Percentage Change in Portfolio Average List Price and Net Price — Novartis explicitly states 'Not reported' in the 2025 SASB Index report (replaced by the group-wide net sales pricing impact metric Pricing impact in % pts cc in Form 6-K).

Data updated 2026-11-02.